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Abstract In December of 2016, a Consensus Conference on
unruptured AVM treatment, involving 24 members of the
three European societies dealing with the treatment of cerebral
AVMs (EANS, ESMINT, and EGKS) was held inMilan, Italy.
The panel made the following statements and general recom-
mendations: (1) Brain arteriovenous malformation (AVM) is a
complex disease associated with potentially severe natural
history; (2) The results of a randomized trial (ARUBA) cannot
be applied equally for all unruptured brain arteriovenous
malformation (uBAVM) and for all treatment modalities; (3)
Considering the multiple treatment modalities available, pa-
tients with uBAVMs should be evaluated by an interdisciplin-
ary neurovascular team consisting of neurosurgeons,
neurointerventionalists, radiosurgeons, and neurologists expe-
rienced in the diagnosis and treatment of brain AVM; (4)
Balancing the risk of hemorrhage and the associated restric-
tions of everyday activities related to untreated unruptured
AVMs against the risk of treatment, there are sufficient
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indications to treat unruptured AVMs grade 1 and 2 (Spetzler–
Martin); (5) There may be indications for treating patients
with higher grades, based on a case-to-case consensus deci-
sion of the experienced team; (6) If treatment is indicated, the
primary strategy should be defined by the multidisciplinary
team prior to the beginning of the treatment and should aim
at complete eradication of the uBAVM; (7) After having con-
sidered the pros and cons of a randomized trial vs. a registry,
the panel proposed a prospective European Multidisciplinary
Registry.
Keywords Unruptured brain AVM .Arteriovenous
malformation . Consensus Conference . EANS . EGKS .
ESMINT . ARUBA
In 2014, ARUBA, a randomized trial comparing intervention-
al therapy and medical management of unruptured brain arte-
riovenous malformations (uBAVMs) [23] concluded that the
natural history of uBAVMs is better than any form of treat-
ment. This may have resulted, intentionally or by chance, in
significantly altered treatment decisions for uBAVMs.
Although the ARUBA Study is internally valid, it has been
the object of many criticisms by the scientific community [5,
11, 18, 20] because of its perceived lack of external validity as
its message does not match the results of many published
reports [3, 7, 12, 14–16, 24, 30, 31, 33, 36, 37, 39, 40] and
the experience of the clinicians dealing with uBAVMs. The
main criticisms relate to the wide heterogeneity of treatment
modalities, the absence of subgroup analyses, the lack of de-
tails on the results of specific treatments, an insufficient
follow-up period (less than 3 years) for the anticipated time
to benefit from treatment, a small patient population, and the
bias related to the high-stakes and irreversible consequences
influencing the decision to be randomized. These biases, as-
sociated with a contentious interpretation of the results, lead to
an assumption that cannot be generalized to all uBAVMand to
all treatment modalities.
As these conclusions are not shared by most of the physi-
cians who treat uBAVMs, it was widely felt that there was the
need to overcome the dilemma created by the publication of
this study.
For this reason, we decided to carry out a Consensus
Conference on AVM treatment at a European level, involving
the three European societies dealing with the treatment of this
disease: the European Association of Neurosurgical Societies
(EANS), the European Society of Interventional Therapy
(ESMINT), and the European Society for Radiosurgery
(EGKS). These societies were instrumental in the selection
of the participants.
The preparatory work and the conduction of the Consensus
Conference were coordinated by a neurologist and
methodologist from the Mario Negri Institute, an internation-
ally renowned Italian Research Institute.
There were 24 participants (Table 1). In the 6 months pre-
ceding the date of the Consensus Conference, a questionnaire
survey was undertaken with the participants to explore the
therapeutic strategies for patients with uBAVMs (with indica-
tions and contraindications) based on their background and
experience.
The meeting was held in Milan on December 1, 2016. The
purpose was to discuss, jointly, directions and methods of
treatment of uBAVMwith the aim of producing a shared doc-
ument. The meeting was conducted following the questions
posed in the survey. The first few questions regarded the gen-
eral opinion of the participants concerning the results of the
ARUBA Study. A more detailed discussion followed on sin-
gle aspects of the treatment of uBAVMs dealing with the par-
ticular problems and nuances of each of the three therapeutic
options (surgery, radiosurgery, endovascular treatment). At
the end of the meeting, a joint document was written.
All the participants of the meeting have checked the present
final paper again.
General questions addressed for the management of
uBAVMs
& Is your experience in accordance with the main message
of the ARUBA Study, i.e., that unruptured AVMs have a
better prognosis if not treated?
All the participants affirmed that the message of the
ARUBA Study cannot be generalized to all unruptured
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AVMs and to all the treatment modalities. The biases of that
study are well known and have been described in many
publications.
& Do you think that some unruptured AVMs have to be
treated?
All the participants answered positively. Some uBAVMs
are difficult and dangerous to treat, but some of them can be
treated with low risk.
Single aspects on the risk of bleeding and the treatment of
uBAVMs:
& Do you think that there are elements that increase the risk
of bleeding in an unruptured AVM?
According to the survey, the panel answered that aneu-
rysms (95%), venous patterns (75%), and location (35%) of
the uBAVMs were, in decreasing order, associated with a
higher incidence of bleeding.
According to a recent review of the literature, no clear risk
factors for bleeding can be identified. According to some re-
ports [1, 10, 21], size and infratentorial location are the two
most common factors associated with bleeding. However,
there was no general agreement on the results of these studies
and the panel concluded that, at present, no definite risk fac-
tors for bleeding have been identified. Importantly, also, no
factor whose absence protects the patients from bleeding has
been identified.
& Is eloquence a contraindication to treatment?
Eloquence was considered a serious problem only for sur-
gery, as two (9%) endovascular radiologists accounted size
more relevant than eloquence.
For surgery, eloquence is the main concern. In their
Surgical Grading Scale, Spetzler–Martin consider elo-
quence as one of the main issues [35, 36]. Eloquence is a
relevant issue also in the Supplementary Grading Scale by
Lawton [17]. Large size and deep venous drainage can
affect eloquence thorough the involvement of the deep
white matter.
For two (9%) surgeons, eloquence is not an issue for
Spetzler–Martin grade 1 or 2 malformations while it becomes
a problem for those in grade 3 or higher [26].
All the panelists agreed that a limited visual deficit can be
compensated, with a small impact in terms of quality of life, to
be taken into account in proposing a treatment to the patient.
Eloquence was considered by all panelists a strong sugges-
tion to choose radiosurgery rather than other treatment
modalities.
& Is young age a contraindication to treatment?
In the survey, younger age was not considered a reason to
withhold treatment by all the participants and surgery was
suggested by 85% of the panel [9, 28, 32].
Although the panel agreed that treatment complications
may overcome a future risk of bleeding, it concluded that in
a young person’s life expectancy is long and in low-grade
malformations the risk of bleeding for the rest of their life is
far superior than the complications of treatment. Moreover,
children will compensate a mild deficit more easily than
adults. Literature reports that for low-grade AVMs the cross-
over between serious neurological complications due to treat-
ment vs. natural history is under 5 years [3, 5].
It was pointed out that knowing to have an AVM is an
important limitation in a patient’s quality of life and that at
least one-third of patients with an uBAVMs are not asymp-
tomatic. They can have severe headache or epilepsy.
Moreover, the risk of surgical or endovascular treatment is
probably lower in young patients that in older people.
Radiosurgeons suggested that Gamma Knife (GK) for
malformations in young patients appears to be more effective
than in older people, and 96% of the panel disagreed with the
option of waiting for a treatable uBAVM to bleed before sug-
gesting treatment.
& Is old age (>65 years) a contraindication to treatment?
In patients over 65, treatment was considered contraindi-
cated by most of the panel because the risk of treatment can
outweigh the risk of bleeding. Most (84%) of the panel agreed
that only a life expectancy over 20 years could be a prerequi-
site for treatment. However, radiosurgeons suggested that as
radiosurgery is a low-risk treatment, it can be suggested also at
an older age.
& Is small size a contraindication to treatment?
Small malformations are less susceptible to the risks of
treatment and have a greater chance of being cured [17, 33].
All three modalities of treatment can be used, but there was
general agreement that a multidisciplinary discussion has to be
performed prior to the treatment, with the aim of defining the
best strategy to obtain a complete cure with lower risks.
As a general rule, 67% of the panel agreed that in a small
non-eloquent uBAVM, surgery is preferable (with or without
previous embolization), 22% indicated Gamma Knife, and
11% endovascular treatment as a first option. In contrast, in
a small eloquent uBAVM, radiosurgery is the best option. This
recommendation is supported by published reports [4, 13, 38].
In selected cases, endovascular treatment may be considered.
Everyone agreed that in small non-eloquent uBAVMs a
treatment has always to be suggested.
& Is large size a contraindication to treatment?
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Large-size uBAVMs were considered by 84% of the
panel a reason to withhold treatment. From a surgical point
of view, grade IV and V malformations are generally con-
sidered not treatable [26, 36] because the surgical risk is
very high. Reducing the malformation size with repeated
endovascular sessions did not prove to reduce the bleeding
risk and, on the contrary, seemed to increase the risk of
complications [6, 19, 22].
In accordance with the fact that bigger malformations seem
to have a higher risk of bleeding and are more likely to be
symptomatic, a staged radiosurgery treatment can be sug-
gested as investigational therapy to downgrade the malforma-
tion size [2, 25, 27, 34]. Staged radiosurgery can be followed
by surgery or endovascular treatment if not completely
effective.
& Are deep feeders a contraindication to treatment?
Lawton first found that deep feeder supply was associated
with a worse outcome [8], but in a subsequent paper [17], this
association was less evident. Today’s surgical instruments,
such as non-stick bipolar, are more effective in favoring coag-
ulation. If there are few single deep feeders, they can be se-
lectively embolized prior to surgery, although endovascular
panelists do not consider selective embolization a low-risk
procedure.
Deep feeders are considered a surgical problem when they
involve several lenticulo-striatal vessels [29], but they are not
a contraindication for radiosurgery.
& Are deep-seated malformations a contraindication to
treatment?
In most of the cases they are a problem for surgery but not
for radiosurgery or endovascular treatment.
& Is diffuseness a contraindication to treatment?
Diffuseness is a problem for all of the three disciplines [8,
17, 38]. Defining the diffuseness is not easy. Most of the panel
agreed that MRI in conjunction with angiography can help to
identify the sparseness of the nidus. Superficial pial vessel
recruitment in some cases can bemisinterpreted as diffuseness
when evaluated only on angiographic projections and has to
be distinguished from true diffuseness.
& Should a new randomized trial be proposed or a Registry
can be better?
There was an agreement that practical experience has to be
translated in numbers to provide a more solid scientific basis
to overcome the ARUBA impasse. In accordance with the
methodologist, the panel agreed that even though another
randomized trial can have disadvantages, it is very difficult
to accomplish and, as happened with the ARUBA Study, can
fail on the patient’s recruitment. Moreover, randomization re-
quires a high level of uncertainty, and in many high-volume
centers this may not be an option. A prospective Multicenter
International Registry can be more easily conducted and will
provide more reliable results on uBAVM treatment. A registry
is a valuable option for assessing treatment effectiveness for a
number of reasons, including the enrollment of a homoge-
neous inception cohort (e.g., at the time of diagnosis), the
inclusion of patients from different sources, the adoption of
pre-planned outcome measures, the minimization of drop-
outs, the standardization of baseline variables (including prog-
nostic predictors), and the allowance for sufficient follow-up
for the outcomes to me measured.
At the end of the day, the panel made the following state-
ments and general recommendations on behalf of the
European Societies of Neurosurgery, Interventional Therapy
and Radiosurgery:
○ Brain arteriovenous malformation (AVM) is a complex disease asso-
ciated with potentially severe natural history.
○ The results of a randomized trial (ARUBA) cannot be applied equally
for all unruptured brain arteriovenous malformation (uBAVM) and for
all treatment modalities.
○ Considering the multiple treatment modalities available, patients with
uBAVMs should be evaluated by an interdisciplinary neurovascular
team consisting of neurosurgeons, neurointerventionalists,
radiosurgeons, and neurologists experienced in the diagnosis and
treatment of brain AVM.
○ Balancing the risk of hemorrhage and the associated restrictions of
everyday activities related to untreated unruptured AVMs against the
risk of treatment, there are sufficient indications to treat unruptured
AVMs grade 1 and 2 (Spetzler–Martin).
○ There may be indications for treating patients with higher grades, based
on a case to case consensus decision of the experienced team.
○ If treatment is indicated, the primary strategy should be defined by the
multidisciplinary team prior to the beginning of the treatment and
should aim at complete eradication of the uBAVM.
○ The main factors to be taken into account for the management are:
- Treatment-related severe complication rate of <5% for grade 1 and 2
(Spetzler–Martin) malformations
- Life expectancy justifying acceptance of the risk associated with the
selected treatment modality (Severe treatment-related complications
are defined as those resulting in unprecedented permanent disability
(mRS 2–6) at 12 months)
○ After having considered the pros and cons of a randomized trial vs. a
registry, the panel proposed a prospective European Multidisciplinary
Registry.
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